-+ 0.00%
-+ 0.00%
-+ 0.00%

Camurus, Gubra to Collaborate on Hypoparathyroidism Therapy

MT Newswires·12/16/2025 06:25:57
Listen to the news
06:25 AM EST, 12/16/2025 (MT Newswires) -- Camurus (CAMX.ST) and Gubra signed an exclusive partnership and license agreement to jointly develop a long-acting treatment for patients with hypoparathyroidism. The collaboration will combine the Swedish biopharmaceutical company's FluidCrystal drug delivery technology with Gubra's parathyroid hormone analog for extended dosing, according to a Tuesday release. Camurus is in charge of drug development and commercialization under the license deal, while Gubra will have the option to co-fund the development and receive tiered royalties based on its financial participation.